Posted by Michael Wonder on 10 May 2023
Acrivon Therapeutics announces FDA grants fast track designation for development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer
9 May 2023 - In previous Phase 2 clinical trials involving more than 400 patients, ACR-368 produced deep, durable monotherapy responses, including complete responses, in a proportion of patients with solid tumours, including platinum-resistant ovarian cancer.
Acrivon Therapeutics today announced that the company has been granted two fast track designations by the US FDA for the development of ACR-368 in platinum-resistant ovarian cancer and endometrial cancer.
